P11 is potent antagonist of the integrin αvβ3-vitronectin interaction (IC50 = 25.72 nM). It can blocks proliferation and induces apoptosis in HUVECs. It exhibits antiangiogenic property.
p11 alone can associate with the plasma membrane in the absence of ANX2 and facilitate plasmin activation and invasiveness in colorectal cancer cells. Upregulation of p11 has been reported in several cancers including renal cell carcinoma, squamous non-cell lung cancer, anaplastic large cell lymphoma, and pediatric intracranial ependymoma. However, the role of the p11 in the development and progression of acute lymphoblastic leukemia has not been intensely investigated.
Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More